About bioMerieuxAdvancing Diagnostics to Improve Public HealthA world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached euro 1.223 billion with 85% of sales outside of France.
bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).
Other information can be found at www.biomerieux.com.
(1) Stal, O., et. al., Validation of prognostic utility of HOXB13:IL17BR and molecular grade index in early stage breast cancer [abstract #77]. 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. December 2009.bioTheranostics ContactsTim Schofield
Michele ParisiTel: +1 858 587 5890
Tel: +1 925 429 firstname.lastname@example.org
Copyright©2010 PR Newswire.
All rights reserved